Printer Friendly

Chelsea Therapeutics Inc.

But Chelsea Therapeutics Inc. (Nasdaq) lost about two-thirds of its market value after the company's experimental drug to treat a neurological disorder missed the main goal of a late-stage study, confirming some apprehension that the trial design could skew results from the control arm. The company said the drug did not demonstrate a statistically significant improvement, measured by the mean score of dizziness or light-headedness of Orthostatic Hypotension Symptom Assessment, compared to a dummy drug. Chelsea is developing the drug, Droxidopa, as a treatment for symptomatic neurogenic orthostatic hypotension (NOH)--a neurological disorder that causes blood pressure to drop when the afflicted person assumes a standing position. Company shares closed the week down $4.17 to $2.73.
COPYRIGHT 2009 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Medical Stock Spotlight
Article Type:Brief article
Geographic Code:1USA
Date:Sep 28, 2009
Previous Article:Nektar Therapeutics Inc.
Next Article:Study finds even more may benefit from Statins.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters